Serina Therapeutics Inc., a clinical-stage biotechnology company, has released its financial results for the second quarter ending June 30, 2025. The company reported a net loss of $6.4 million for the quarter, a significant turnaround from the net income of $5.2 million in the same period in 2024. Revenue for the quarter increased to $130,000, up from $51,000 in the corresponding period last year, with revenues entirely derived from grants provided by the National Institutes of Health. Operating expenses rose to $5.7 million from $3.9 million in the previous year, contributing to the overall net loss. Cash and cash equivalents stood at $6.0 million as of June 30, 2025, with projections indicating that these funds will support operations into the fourth quarter of 2025. In terms of business developments, Serina secured $5 million in funding from strategic shareholders in April 2025 to advance the development of SER-252, its lead candidate for treating advanced Parkinson's disease. Additionally, the company initiated an at-the-market offering program with the potential to raise $13.3 million through share sales, having already issued shares worth $1.2 million by early August 2025. The company is preparing to commence a Phase 1 clinical trial for SER-252 in the fourth quarter of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.